Free Trial

Iovance Biotherapeutics (IOVA) News Today

→ Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad)
Free IOVA Stock Alerts
$7.78
-0.36 (-4.42%)
(As of 06/7/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends
June 8 at 4:00 PM | marketbeat.com
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Sold by Sectoral Asset Management Inc.
Sectoral Asset Management Inc. trimmed its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 79.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 198,800 shares of the biote
June 6 at 4:43 AM | marketbeat.com
UBS Group AG Purchases 615,920 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
UBS Group AG boosted its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 255.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 857,308 shares of the biotechnology company's stock after
June 5 at 8:33 AM | marketbeat.com
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Position Reduced by Rafferty Asset Management LLC
Rafferty Asset Management LLC cut its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 16.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,247,515 shares of the biotec
June 4, 2024 | marketbeat.com
Rhenman & Partners Asset Management AB Increases Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Rhenman & Partners Asset Management AB grew its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 17.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,116,818 shares of the bi
June 4, 2024 | americanbankingnews.com
Brokers Issue Forecasts for Iovance Biotherapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:IOVA)
June 3, 2024 | marketbeat.com
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Sold by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP trimmed its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 11.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,516,987 shares of the biotechnology
June 3, 2024 | marketbeat.com
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Expected to Earn Q2 2024 Earnings of ($0.38) Per Share
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Research analysts at Zacks Research upped their Q2 2024 earnings per share (EPS) estimates for shares of Iovance Biotherapeutics in a report issued on Wednesday, May 29th. Zacks Research analyst S. Ganoria now expects that the biotechnol
June 1, 2024 | americanbankingnews.com
Iovance Biotherapeutics' (IOVA) Buy Rating Reaffirmed at HC Wainwright
May 31, 2024 | marketbeat.com
HC Wainwright Reiterates "Buy" Rating for Iovance Biotherapeutics (NASDAQ:IOVA)
HC Wainwright restated a "buy" rating and issued a $32.00 price objective on shares of Iovance Biotherapeutics in a research report on Friday.
May 30, 2024 | marketbeat.com
Corient Private Wealth LLC Has $2.98 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Corient Private Wealth LLC raised its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 206.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 367,000 shares o
May 29, 2024 | markets.businessinsider.com
Piper Sandler Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)
May 29, 2024 | marketbeat.com
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Sold by Artisan Partners Limited Partnership
Artisan Partners Limited Partnership lessened its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 4.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,827,670 shares of the biotechnology company's s
May 29, 2024 | markets.businessinsider.com
Analysts Conflicted on These Healthcare Names: Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals Inc (AMLX) and Vaxcyte (PCVX)
May 24, 2024 | msn.com
What's Going On With Iovance Biotherapeutics Today?
May 24, 2024 | globenewswire.com
Iovance Biotherapeutics to Present at Upcoming Conferences and Events
May 24, 2024 | marketbeat.com
Iovance Biotherapeutics (NASDAQ:IOVA) Given "Buy" Rating at HC Wainwright
HC Wainwright reissued a "buy" rating and set a $32.00 target price on shares of Iovance Biotherapeutics in a report on Friday.
May 23, 2024 | globenewswire.com
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
May 22, 2024 | marketbeat.com
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Sold by Great Lakes Advisors LLC
Great Lakes Advisors LLC reduced its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 50.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 136,183 shares of the biotechnology compa
May 22, 2024 | fool.com
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
May 22, 2024 | marketbeat.com
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Rating of "Buy" from Analysts
Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) have been given an average rating of "Buy" by the ten research firms that are currently covering the firm, Marketbeat Ratings reports. Ten analysts have rated the stock with a buy recommendation. The average 1-year price objec
May 21, 2024 | marketbeat.com
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 3.4%
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 3.4%
May 21, 2024 | marketbeat.com
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Bought by BNP Paribas Financial Markets
BNP Paribas Financial Markets raised its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 83.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 552,847 shares of the biotechnology company's stock after acquiring an a
May 17, 2024 | globenewswire.com
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
May 16, 2024 | fool.com
4 Small-Cap Value Stocks That Could Go Parabolic
May 13, 2024 | benzinga.com
Looking At Iovance Biotherapeutics's Recent Unusual Options Activity
May 13, 2024 | seekingalpha.com
Iovance Biotherapeutics' Amtagvi: Innovative Therapy, Financial Strain (Rating Downgrade)
May 11, 2024 | investorplace.com
The 3 Most Undervalued Biotech Stocks to Buy in May 2024
May 11, 2024 | markets.businessinsider.com
Iovance Biotherapeutics Poised for Growth: Analyst Reiterates Buy Rating Amid Strong Q1 Performance and Promising Clinical Advancements
May 11, 2024 | fool.com
Iovance Biotherapeutics Reports a Q1 Revenue Miss
May 11, 2024 | finance.yahoo.com
Iovance Biotherapeutics Inc (IOVA) Q1 2024 Earnings: Aligns with EPS Projections Amidst Strong ...
May 11, 2024 | msn.com
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2024 Earnings Call Transcript
May 10, 2024 | marketbeat.com
Iovance Biotherapeutics (NASDAQ:IOVA) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS
Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.03. The business had revenue of $0.72 million for the quarter, compared to analyst estimates of $1.99 million. During the same quarter in the prior year, the business earned ($0.50) earnings per share. The firm's quarterly revenue was up 71400.0% compared to the same quarter last year.
May 10, 2024 | benzinga.com
Iovance Biotherapeutics's Options: A Look at What the Big Money is Thinking
May 10, 2024 | seekingalpha.com
Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi
May 10, 2024 | fool.com
Why Iovance Stock Is Down 18% Today
May 10, 2024 | markets.businessinsider.com
Iovance Biotherapeutics: A Strong Buy on Robust Growth Potential and Early Launch Success
May 9, 2024 | investorplace.com
IOVA Stock Earnings: Iovance Biotherapeutics Meets EPS, Misses Revenue for Q1 2024
May 9, 2024 | sfgate.com
Iovance Biotherapeutics: Q1 Earnings Snapshot
May 9, 2024 | finance.yahoo.com
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
May 9, 2024 | globenewswire.com
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
May 6, 2024 | marketbeat.com
Investors Buy High Volume of Call Options on Iovance Biotherapeutics (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) was the target of some unusual options trading activity on Monday. Investors bought 23,866 call options on the company. This is an increase of 44% compared to the typical volume of 16,524 call options.
May 5, 2024 | fool.com
Got $500? These Hot Growth Stocks Are Screaming Buys Right Now
May 2, 2024 | marketbeat.com
Iovance Biotherapeutics (IOVA) to Release Quarterly Earnings on Thursday
Iovance Biotherapeutics (NASDAQ:IOVA) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.
May 2, 2024 | msn.com
First FDA-approved cellular therapy for metastatic melanoma available in South Florida
May 1, 2024 | globenewswire.com
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
May 1, 2024 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Exelixis (EXEL)
April 30, 2024 | globenewswire.com
Iovance Biotherapeutics to Present at Upcoming Conferences
April 28, 2024 | fool.com
Where Will Iovance Biotherapeutics Stock Be in 5 Years?
April 28, 2024 | marketbeat.com
Parametrica Management Ltd Acquires 224,876 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Parametrica Management Ltd lifted its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 235.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 320,276 shares of the biotechnology company's stock
April 27, 2024 | investorplace.com
The Top 3 Biotech Stocks to Buy in April 2024
Get Iovance Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.

Gold Set to EXPLODE! (Ad)

The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing demand from Central Banks and billionaires to EXPLODE! The elites are buying up gold like nothing we've seen before…

Click here now to download the free Precious Metals Buying Guide.

IOVA Media Mentions By Week

IOVA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IOVA
News Sentiment
▼
1.00

0.73
▲
Average
Medical
News Sentiment

IOVA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IOVA Articles
This Week
▼
10

6
▲
IOVA Articles
Average Week

Get Iovance Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:IOVA) was last updated on 6/8/2024 by MarketBeat.com Staff

From Our Partners
Breaking - The US Gov. Seized CITGO
Do you want an investment that can double or triple your money in the next three months? The US Court is cu...
Augury Research | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
Was the Great Financial Crisis fun?
The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...
Brooks Enterprises | Sponsored
Shocking $16T Elon Musk Crypto Leak
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...
Crypto 101 Media | Sponsored
Must-See: Elon’s New Invention is Absolutely Insane
Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...
InvestorPlace | Sponsored
Are You Positioned For The New Energy Goldrush?
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...
Wealthpin Pro | Sponsored